We've updated our Privacy Policy to make it clearer how we use your personal data.
We use cookies to provide you with a better experience, read our Cookie Policy
EP37743
Poster Title: Implementation of Holistic Glycopeptide PASEF-DDA Data In Diagnostics
Submitted on 05 Oct 2021
Author(s): Hans JCT Wessels1, Purva Kulkarni1, Fokje Zijlstra1, Merel Post1, Melissa Bärenfänger1, Pierre-Olivier Schmit2, Alain J van Gool1, Dirk J Lefeber1
Affiliations: 1Translational Metabolic Laboratory, Department of Laboratory Medicine, Radboud university medical center, Nijmegen, the Netherlands; 2 Bruker Daltonique S.A., Wissembourg, France
Poster Views: 42
Submitted on 05 Oct 2021
Author(s): Hans JCT Wessels1, Purva Kulkarni1, Fokje Zijlstra1, Merel Post1, Melissa Bärenfänger1, Pierre-Olivier Schmit2, Alain J van Gool1, Dirk J Lefeber1
Affiliations: 1Translational Metabolic Laboratory, Department of Laboratory Medicine, Radboud university medical center, Nijmegen, the Netherlands; 2 Bruker Daltonique S.A., Wissembourg, France
Poster Views: 42
Abstract: • Holistic PASEF-DDA data is of sufficient quality for use in both biomarker research and diagnostics.
• Glycopeptide workflow for diagnosis of congenital disorders of glycosylation will be implemented in clinical care in 2021
• Use of real-time glycopeptide data processing and reporting by GPU-parallelisation will be explored for next generation workflowsSummary: Advantages of holistic PASEF-DDA data acquisition for clinical applications:
- Single data file can be used for both biomarker research and application
- All possible MS1 and MS/MS data is generated for each sample to enable retrospective analysis of novel biomarkers
- Different disease biomarkers can be evaluated by simply exchanging the glycosylation site targets used for targeted feature extraction
• Glycopeptide workflow for diagnosis of congenital disorders of glycosylation will be implemented in clinical care in 2021
• Use of real-time glycopeptide data processing and reporting by GPU-parallelisation will be explored for next generation workflowsSummary: Advantages of holistic PASEF-DDA data acquisition for clinical applications:
- Single data file can be used for both biomarker research and application
- All possible MS1 and MS/MS data is generated for each sample to enable retrospective analysis of novel biomarkers
- Different disease biomarkers can be evaluated by simply exchanging the glycosylation site targets used for targeted feature extraction
Ask the author a question about this poster.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Related Posters
Real-time search of Ubiquitin diGLY modified peptides and PaSER acquisition control on the timsTOF PRO
Christopher Adams1; Robin Park1; Nagarjuna Nagaraj4; Sven Brehmer4; Matt Willetts3; Elizabeth Gordon3; Barry M. Zee2; Hayley Peckham2; Kimberly Lee2; Tharan Srikumar3
Proteomic profiling of IDH mutant gliomas enables prediction of chromosomal copy number variations
Marius Felix 1 2 Dennis Friedel 1 2 Ashok Kumar Jayavelu 4 Uwe Warnken 3 Damian Stichel 1 2 Christel Herold Mende 5 Laura Heikaus 6 Andreas von Deimling 1 2 and David E Reuss 1 2
OpenTIMS TimsPy TimsR: Open Access to timsTOF Pro Raw Data
Mateusz K. Łącki1, Michał P.Startek2, Sven Brehmer3, Christina Bell3, Ute Distler1, Stefan Tenzer1
Novel bifunctional material coupled to PASEF enables sensitive extracellular vesicles phosphoproteomic analysis of urine
Jie Sun1,2, W.Andy Tao3, Xiaoxian Du4 and Xianming Liu4
Immune suppression in the early stage of COVID 19 disease
Nan Zhang 1 , Siyuan Wang 1 ,Catherine CL Wong 1*,
